Company Focus
Novartis
Latest Novartis News
Biotechnology
Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease, when the Swiss pharma giant’s shares edged up 2.2% to 2.09 francs. 11 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Novartis
Biotechnology
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate slowing of decline, with most participants having completed treatment, US pharma major Eli Lilly announced today. 4 August 2025
Biotechnology
Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of its pipeline of long-acting antibody therapies. The company, founded in 2016 and based in Hunan province, lists China International Capital Corporation as the sole sponsor. 4 August 2025
Pharmaceutical
Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s CSPC Pharma for rights to a GLP-1 receptor inhibitor, SYH 2086, to compliment its platform in metabolic dysfunction associated steatohepatitis (MASH) – led by Rezdiffra. US President Donald Trump issued an ultimatum to a number of major pharmaceutical companies demanding that they reduce the price of their drugs in the USA. Also of note, LENZ Therapeutics received US Food and Drug Administration (FDA) approval for its VIZZ, the first aceclidine-based drug for the treatment of presbyopia in adults. 3 August 2025
Pharmaceutical
US RNA interference (RNAi) specialist Arrowhead Pharmaceuticals today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France’s Sanofi to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China. 2 August 2025
Biotechnology
US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business update.
Revenue grew by 4% year-over-year to $3.68 billion, outpacing forecasts of $3.30 billion. 1 August 2025
Biotechnology
US biotech major Biogen reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion. 1 August 2025
Pharmaceutical
US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. 1 August 2025
Generics
Second quarter 2025 revenues at Teva Pharmaceutical Industries came in at $4.18 billion, flat in US dollars, or a decrease of 1% in local currency terms, compared to the same period of 2024. 31 July 2025
Pharmaceutical
Bristol Myers Squibb has posted better-than-expected second-quarter 2025 results, driven by strong sales of its blood thinner Eliquis (apixaban) and cancer treatments Opdivo (nivolumab) and Revlimid (lenalidomide). 31 July 2025
Pharmaceutical
Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter financial results and latest guidance. 31 July 2025
Latest In Brief for Novartis
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze